Plasma levels of polyunsaturated fatty acids and multiple sclerosis susceptibility in a US case-control study

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY

Multiple sclerosis and related disorders Pub Date : 2024-10-06 DOI:10.1016/j.msard.2024.105920

Eleanor Dunlop , Alison Daly , Trevor A. Mori , Annette Langer-Gould , Gavin Pereira , Lucinda J. Black

{"title":"Plasma levels of polyunsaturated fatty acids and multiple sclerosis susceptibility in a US case-control study","authors":"Eleanor Dunlop , Alison Daly , Trevor A. Mori , Annette Langer-Gould , Gavin Pereira , Lucinda J. Black","doi":"10.1016/j.msard.2024.105920","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>There are plausible mechanisms, yet mixed evidence, that higher polyunsaturated fatty acids (PUFAs) levels reduces the risk of multiple sclerosis (MS). Prior studies relied on dietary surveys to estimate levels.</div></div><div><h3>Objective</h3><div>We tested associations between plasma levels of <em>n</em>-3 and <em>n</em>-6 PUFAs and likelihood of MS onset or clinically isolated syndrome (CIS) using data from the MS Sunshine Study, a case-control study conducted in the United States.</div></div><div><h3>Methods</h3><div>Case participants (<em>n</em> = 589) aged ≥ 18 years and matched control participants (<em>n</em> = 630) were recruited between 2011 and 2015. Plasma phospholipid fatty acid profiling was conducted by gas-liquid chromatography. We used logistic regression to report odds ratios, testing for interactions, adjusting for covariates and correcting for multiple comparisons.</div></div><div><h3>Results</h3><div>There was a 6 % lower probability of MS/CIS per unit increase in total <em>n</em>-6 PUFA level, expressed as a percentage of total plasma phospholipid fatty acids (odds ratio = 0.94; 95 % confidence interval = 0.90,0.98; <em>p</em> = 0.012). We found no statistically significant association between individual or total plasma levels of <em>n</em>-3 PUFAs and probability of MS/CIS; however, plasma levels of <em>n</em>-3 PUFAs were low across the cohort. No other individual or aggregate PUFA levels were significantly associated with MS/CIS.</div></div><div><h3>Conclusion</h3><div>A higher total <em>n</em>-6 PUFA level may be beneficial in terms of MS susceptibility.</div><div>Further research is needed to determine whether <em>n</em>-3 PUFAs may be beneficial only above a threshold that is achievable by supplementation.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105920"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034824004966","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

There are plausible mechanisms, yet mixed evidence, that higher polyunsaturated fatty acids (PUFAs) levels reduces the risk of multiple sclerosis (MS). Prior studies relied on dietary surveys to estimate levels.

Objective

We tested associations between plasma levels of n-3 and n-6 PUFAs and likelihood of MS onset or clinically isolated syndrome (CIS) using data from the MS Sunshine Study, a case-control study conducted in the United States.

Methods

Case participants (n = 589) aged ≥ 18 years and matched control participants (n = 630) were recruited between 2011 and 2015. Plasma phospholipid fatty acid profiling was conducted by gas-liquid chromatography. We used logistic regression to report odds ratios, testing for interactions, adjusting for covariates and correcting for multiple comparisons.

Results

There was a 6 % lower probability of MS/CIS per unit increase in total n-6 PUFA level, expressed as a percentage of total plasma phospholipid fatty acids (odds ratio = 0.94; 95 % confidence interval = 0.90,0.98; p = 0.012). We found no statistically significant association between individual or total plasma levels of n-3 PUFAs and probability of MS/CIS; however, plasma levels of n-3 PUFAs were low across the cohort. No other individual or aggregate PUFA levels were significantly associated with MS/CIS.

Conclusion

A higher total n-6 PUFA level may be beneficial in terms of MS susceptibility.

Further research is needed to determine whether n-3 PUFAs may be beneficial only above a threshold that is achievable by supplementation.

查看原文本刊更多论文

美国病例对照研究中的血浆多不饱和脂肪酸水平与多发性硬化症易感性

背景提高多不饱和脂肪酸（PUFAs）水平可降低多发性硬化症（MS）发病风险的机制似是而非，但证据不一。我们利用在美国进行的一项病例对照研究--多发性硬化症阳光研究（MS Sunshine Study）的数据，检验了血浆中 n-3 和 n-6 PUFAs 水平与多发性硬化症发病或临床孤立综合征（CIS）可能性之间的关系。血浆磷脂脂肪酸分析采用气液相色谱法进行。结果以血浆磷脂脂肪酸总量的百分比表示，n-6 PUFA总量每增加一个单位，MS/CIS的发病概率就降低6%（几率比=0.94；95%置信区间=0.90,0.98；P=0.012）。我们发现，n-3 PUFAs 的单个或总血浆水平与 MS/CIS 发生概率之间没有统计学意义上的显著关联；但是，整个队列中 n-3 PUFAs 的血浆水平较低。结论较高的 n-6 PUFA 总含量可能对 MS 易感性有益，但 n-3 PUFA 是否只有在通过补充达到的阈值以上才有益，还需要进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.